Tag: NIH
Vaxxas to develop first room-temperature stable RSV vaccine with NIH license
Vaxxas, a clinical-stage biotechnology company known for its innovative high-density microarray patch (HD-MAP) vaccination platform, has secured a worldwide license from the United States National Institutes of Health (NIH) for a next-generation vaccine antigen aimed at combating Respiratory Syncytial Virus (RSV).Â
Featured Article
Behind the Australian Made logo: Six manufacturers shaping local industry
Australian manufacturers are continuing to invest in local production, innovation and sustainability across a wide range of industries. From textiles and packaging to construction and advanced manufacturing, Australian Made licensees are developing products tailored to local conditions while supporting Australian jobs and capabilities.
